News Sentiment

WHWK sentiment intelligence

Whitehawk Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.97 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-5.3% over one week, -4.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Sees Large Increase in Short Interest

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -5.3% Price reacting lower
Trend fit Trend active -4.6% over four weeks
Fair value 44.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 41
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 14
Stock Titan 12
Market source 8
PR Newswire 5
simplywall.st 3
MarketBeat 2
Finviz 2
StockStory 1

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 18
Analyst action 5
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
MarketBeat Direct company coverage

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Sees Large Increase in Short Interest

Whitehawk Therapeutics (NASDAQ:WHWK) experienced a substantial 139.9% increase in short interest during June, reaching 2.83 million shares. Despite this bearish sentiment, which represents 11.4% of the float and a 3.4-day days-to-cover ratio, analysts generally maintain a bullish

Tone
Negative 40/100
Event
Market update
Published
14 Jul 2026 11:11
Source
MarketBeat
TradingView Direct company coverage

Price to book forward of Whitehawk Therapeutics, Inc. – HAM:3350

This article provides the title "Price to book forward of Whitehawk Therapeutics, Inc. – HAM:3350" but contains no substantive content beyond navigation and boilerplate website elements. It indicates the stock (HAM:3350) is listed on the Hamburg Stock Exchange and has no discerni

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 15:09
Source
TradingView
MarketBeat Direct company coverage

Whitehawk Therapeutics (NASDAQ:WHWK) Earns Outperform Rating from Analysts at Leerink Partners

Leerink Partners initiated coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with an "outperform" rating and a $9.00 price target, suggesting a significant upside. The stock holds a "Moderate Buy" consensus among analysts with an average target price of $8.20. While the company re

Tone
Positive 77/100
Event
Analyst action
Published
13 Jul 2026 13:09
Source
MarketBeat
Market source Direct company coverage

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Biocytogen and Whitehawk Therapeutics announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Using Biocytogen's RenLite® platform for bispecific antibodies and Whitehawk's ADC linker-payload platform, they aim to create differentiated therapeutic

Tone
Positive 71/100
Event
Market update
Published
08 Jul 2026 00:09
Source
Market source
Finviz Direct company coverage

WHWK - Whitehawk Therapeutics Inc Options

This article provides a detailed financial overview of Whitehawk Therapeutics Inc. (WHWK), including its recent stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights the company's valuation ratios, profitability,

Tone
Neutral 50/100
Event
Analyst action
Published
05 Jul 2026 09:40
Source
Finviz
Finviz Direct company coverage

WHWK - Whitehawk Therapeutics Inc Latest SEC Filings

This article provides a detailed financial overview of Whitehawk Therapeutics Inc (WHWK), including its stock performance, key financial metrics, insider and institutional ownership, and various ratios. It covers the latest stock price, changes, market capitalization, earnings pe

Tone
Negative 35/100
Event
Earnings
Published
04 Jul 2026 01:41
Source
Finviz
TradingView Direct company coverage

Price to sales forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK

This page displays the "Price to sales forward" metric for Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) on TradingView. The article is very sparse, showing only the company name, stock ticker, and the specific financial metric. It appears to be a stub or a data point within a larg

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 17:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. – FWB:3350

This article displays the "Enterprise value to revenue forward" metric for Whitehawk Therapeutics, Inc. (FWB:3350), listed on the Frankfurt Stock Exchange. The content primarily shows financial data and market information provided by various financial services. It indicates that

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 06:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK

The article discusses the enterprise value to revenue forward for Whitehawk Therapeutics, Inc. (NASDAQ: WHWK). It appears to be a financial data snippet from TradingView, indicating no current trades and providing an overview of the company's financial information, news, and othe

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 17:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Whitehawk Therapeutics, Inc. – FWB:3350

This article provides a brief overview of the "Price to sales forward" metric for Whitehawk Therapeutics, Inc. (FWB:3350) on the Frankfurt Stock Exchange. It lists the period, value, change, and percentage change. The content appears to be a financial data snippet from TradingVie

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 17:10
Source
TradingView
TradingView Direct company coverage

Whitehawk Therapeutics, Inc. Actuals & Estimates (NASDAQ:WHWK)

This article provides an overview of Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), including its current stock price, historical performance, and analyst forecasts. It details financial metrics, past earnings reports, upcoming earnings dates, and general information about the comp

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:39
Source
TradingView
TradingView Direct company coverage

Whitehawk Therapeutics, Inc. Actuals & Estimates (DUS:3350)

This article provides an overview of Whitehawk Therapeutics, Inc. (DUS:3350), detailing its financial actuals and estimates as available on TradingView. It covers analyst forecasts, historical stock prices, recent earnings reports, revenue, net income, employee count, and EBITDA.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 01:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK

This page from TradingView provides financial information for Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), specifically displaying its "Price to earnings forward" metric. The content indicates market status and links to various financial data, tools, and community features offere

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 21:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Whitehawk Therapeutics, Inc. – DUS:3350

This article focuses on the enterprise value to revenue forward for Whitehawk Therapeutics, Inc. (DUS:3350), traded on the Dusseldorf Stock Exchange. It presents financial overview, news, community, forecasts, seasonals, and ETF information related to the company. The text is pri

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 14:41
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Whitehawk Therapeutics, Inc. – DUS:3350

This article provides financial information for Whitehawk Therapeutics, Inc. (DUS:3350) on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-sales ratio. The market was closed at the time of publication, with no trades observed.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 14:10
Source
TradingView
Investing.com Canada Direct company coverage

B.Riley initiates Whitehawk Therapeutics stock rating at Buy on ADC portfolio

B.Riley has initiated coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with a Buy rating and a price target of $10.00, citing the company's three-asset antibody-drug conjugate (ADC) portfolio. The stock is currently trading at $4.52, suggesting significant upside. Whitehawk Thera

Tone
Positive 75/100
Event
Analyst action
Published
25 Jun 2026 13:41
Source
Investing.com Canada
TradingView Direct company coverage

Enterprise value to EBIT forward of Whitehawk Therapeutics, Inc. – NASDAQ:WHWK

This article provides financial information for Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) focusing on its enterprise value to EBIT forward ratio. It is presented in a data-centric format from TradingView, indicating no specific data points but rather a category for financial ana

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 11:41
Source
TradingView
Stock Titan Direct company coverage

Whitehawk Therapeutics (WHWK) director granted 38,040 stock options at $4.16

Whitehawk Therapeutics director Mohammad Hirmand was granted 38,040 stock options with an exercise price of $4.16 per share, expiring on June 12, 2036. These options will fully vest on the earlier of one year from the grant date or the day before the next annual stockholder meeti

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 14:09
Source
Stock Titan
Stock Titan Direct company coverage

Whitehawk Therapeutics (WHWK) director receives 38,040 stock options grant

Whitehawk Therapeutics director Baiteng Zhao was granted 38,040 stock options as compensation, with an exercise price of $4.16 per share and an expiration date of June 12, 2036. The options will vest 100% after approximately one year or just before the next annual stockholder mee

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 13:39
Source
Stock Titan
Stock Titan Direct company coverage

Director Richard Maroun receives 38,040 stock options at Whitehawk (WHWK)

Whitehawk Therapeutics director Richard E. Maroun has been granted 38,040 stock options with an exercise price of $4.16 per share, expiring on June 12, 2036. The options will vest in a single tranche on the earlier of one year from the June 12, 2026 grant date or the day before t

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 01:40
Source
Stock Titan
Stock Titan Direct company coverage

Whitehawk Therapeutics (WHWK) director receives 38,040 stock options at $4.16

Whitehawk Therapeutics director Neil Desai was granted 38,040 stock options at an exercise price of $4.16 per share, expiring on June 12, 2036. The options vest 100% on the earlier of one year from the grant date or the day before the next annual stockholder meeting, contingent o

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 01:40
Source
Stock Titan
Stock Titan Direct company coverage

Whitehawk (WHWK) grants 38,040 stock options to director Aghazadeh

Whitehawk Therapeutics, Inc. (WHWK) director and 10% owner Behzad Aghazadeh was granted 38,040 stock options with an exercise price of $4.16 per share, expiring on June 12, 2036. The options will vest in a single tranche on the earlier of one year from the grant date (June 12, 20

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 01:10
Source
Stock Titan
Stock Titan Direct company coverage

Whitehawk Therapeutics (WHWK) director granted options on 38,040 shares

Whitehawk Therapeutics director Caley Castelein has been granted stock options for 38,040 shares of the company's common stock, as disclosed in a recent Form 4 filing. The options have an exercise price of $4.16 per share and an expiration date of June 12, 2036. The shares will v

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 01:10
Source
Stock Titan
Investing.com Direct company coverage

Whitehawk Therapeutics shareholders elect directors and approve proposals at annual meeting

Whitehawk Therapeutics (NASDAQ:WHWK) held its annual meeting, where shareholders elected three Class III directors, approved executive compensation on an advisory basis, and ratified the appointment of BDO USA, P.C. as their independent accounting firm. These decisions, based on

Tone
Positive 70/100
Event
Market update
Published
13 Jun 2026 12:39
Source
Investing.com
Stock Titan Direct company coverage

Shareholders of Whitehawk Therapeutics (NASDAQ: WHWK) approve directors, pay and auditor

Whitehawk Therapeutics (NASDAQ: WHWK) announced the results of its 2026 annual meeting of stockholders, where investors approved the election of three Class III directors, advisory compensation for named executive officers, and the ratification of BDO USA, P.C. as the independent

Tone
Neutral 50/100
Event
Earnings
Published
12 Jun 2026 20:39
Source
Stock Titan